Table 1.
Participant demographics, baseline data and clinical outcomes.
| P1 | P2 | P3 | |
|---|---|---|---|
| Age/sex | 76/m | 56/m | 68/m |
| Malignancy | Merkel Cell Carcinoma | Metastatic Melanoma | Metastatic Melanoma |
| Previous therapy | Carboplatin and etoposide | Dabrafenib and trametinib | Radiotherapy |
| Immune checkpoint blockade | Avelumab (anti-PDL1) 10mg/kg 2 weekly |
Nivolumab (anti-PD1) 3mg/kg + Ipilimumab (anti-CTLA4) 1mg/kg 3 weekly |
Nivolumab 3mg/kg + Ipilimumab 1mg/kg 3 weekly |
| Year of HIV Diagnosis | 2007 | 2001 | 2003 |
| ART at enrolment | TDF/3TC/EFV | TDF/3TC/EFV | EVG /COBI/TAF/FTC |
| CD4 nadir | 53 cells/uL | 210 cells/uL | 125 cells/uL |
| Baseline CD4 | 323 cells/uL | 468 cells/uL | 265 cells/uL |
| Progress | Partial response Died 4 months after ICB commenced |
Disease progression Died 2 months after ICB commenced |
Disease responsive Maintenance nivolumab |
P, participant; VL, viral load; BL, baseline; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine; FTC, emtricitabine; EFV, efavirenz; EVG, elvitegravir; COBI, cobicistat; TAF, tenofovir alafenamide; ICB, immune checkpoint blockade.